Event summary produced by The Globe and Mail Events team. The Globe’s editorial department was not involved.

Tesla stock rises sharply extending gains for a second day, Nvidia and Palantir shares trade higher as tech stocks bounce ...

Wondering if you should look beyond American markets to build your fortune? This widely held international fund offers a few ...

PARIS] Ozempic-maker Novo Nordisk is planning to make more of its medicines for the US market in the country; Boeing risks a ...

U.S. equities were mixed at midday as the markets weighed a better-than-expected report on inflation and more tariff news.

In corporate suites, executives are counting the potential cost of the tariffs, its impact on sales, profits and market shares.

The report highlighted that Novo Nordisk currently charges Americans $969 a month for diabetes therapy Ozempic, but just $155 in Canada and $59 in Germany. Similarly, the list price for obesity ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

After America imposed a 25% tariff on steel and aluminium on March 12th, it said it would charge punitive levies on €8bn ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.